193
Views
9
CrossRef citations to date
0
Altmetric
Article

POSTTRANSPLANT ORAL IRON-CHELATING THERAPY IN PATIENTS WITH β-THALASSEMIA MAJOR

, MD, , MD, , MD, , MD &
Pages 374-379 | Accepted 26 Feb 2010, Published online: 06 Jul 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

M. Akif Yesilipek. (2020) Hematopoietic Stem Cell Transplantation in Patients with Hemoglobinopathies. Hemoglobin 44:6, pages 377-384.
Read now

Articles from other publishers (8)

Alessandro Cattoni, Giulia Capitoli, Sara Casagranda, Paola Corti, Marta Adavastro, Alessandro Molinaro, Filiberto Di Gennaro, Sonia Bonanomi, Andrea Biondi, Stefania Galimberti & Adriana Balduzzi. (2023) Iron Overload Following Hematopoietic Stem Cell Transplantation: Prevalence, Severity, and Management in Children and Adolescents with Malignant and Nonmalignant Diseases. Transplantation and Cellular Therapy 29:4, pages 271.e1-271.e12.
Crossref
Funda T. Kupesiz, Cigdem Sivrice, Aysenur Akinel, Gulen T. Kintrup, Elif Guler & Alphan Kupesiz. (2022) Efficacy and Safety of Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Thalassemia Patients: A Retrospective Observational Study. Journal of Pediatric Hematology/Oncology 44:1, pages e26-e34.
Crossref
Alessandro Isidori, Federica Loscocco, Giuseppe Visani, Martina Chiarucci, Pellegrino Musto, Anne-Sophie Kubasch, Uwe Platzbecker & Francesca Vinchi. (2021) Iron Toxicity and Chelation Therapy in Hematopoietic Stem Cell Transplant. Transplantation and Cellular Therapy 27:5, pages 371-379.
Crossref
Fouzia N. Aboobacker, Gaurav Dixit, Kavitha M. Lakshmi, Anu Korula, Aby Abraham, Biju George, Vikram Mathews & Alok Srivastava. (2021) Outcome of iron reduction therapy in ex-thalassemics. PLOS ONE 16:1, pages e0238793.
Crossref
Mehmet Akif Yesilipek, Gulsun Karasu, Zuhre Kaya, Baris B. Kuskonmaz, Vedat Uygun, Ilkiz Dag, Onur Ozudogru & Mehmet Ertem. (2018) A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major. Biology of Blood and Marrow Transplantation 24:3, pages 613-618.
Crossref
Aurélie Jaspers, Salaheddine Bouhya, Stéphanie Belaiche, Patrice Chevallier, Eric Hermet, Carole Hospital-Gustems, Mauricette Michallet, Fanny Rialland, Olga Samsonova, Anne Sirvent, Ibrahim Yakoub-Agha, Pierre-Simon Rohrlich & Yves Beguin. (2016) Évaluation et prise en charge de la surcharge en fer post-greffe : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bulletin du Cancer 103:11, pages S255-S266.
Crossref
Maria Marsella & Caterina Borgna-Pignatti. (2014) Transfusional Iron Overload and Iron Chelation Therapy in Thalassemia Major and Sickle Cell Disease. Hematology/Oncology Clinics of North America 28:4, pages 703-727.
Crossref
R.H.B. Meyboom. 2012. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions 367 375 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.